LB Pharmaceuticals raises $285M in first major biotech IPO since February

LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ('LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock at a public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from the offering are expected to be $285.0 million before deducting underwriting discounts and commissions and other offering expenses payable by LB P…

LB Pharmaceuticals raises $285M in first major biotech IPO since February

LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for large IPOs in years.

LB Pharma prices $285M Nasdaq debut to help develop schizophrenia drug

LB Pharmaceuticals raises $285M IPO for schizophrenia drug LB-102, trading as LBRX. CEO Heather Turner leads first biotech IPO in 7 months, pricing at $15/share on Nasdaq.

LB Pharmaceuticals raises $285 million in US IPO - Regional Media News

(Reuters) -LB Pharmaceuticals raised $285 million in its U.S. initial public offering, the biotech firm said on Wednesday, marking the first sizable biotech IPO since February. The New York-based firm sold 19 million shares at $15 each, within its marketed range of $14 to $16 apiece. The IPO valued LB at $301.5 million. Companies ranging from crypto to consumer are poised to list their shares on U.S. exchanges this week as the U.S. IPO market ma…